The Pharma Data

OCTOBER 22, 2020

Moderna has completed enrollment of 30,000 participants for its phase 3 study evaluating COVID-19 vaccine candidate mRNA-1273. The randomized, placebo-controlled trial is being conducted in partnership with the NIH’s National Institute of Allergy and Infectious Diseases and HHS’ Biomedical Advanced Research and Development Authority.

Vaccine 52

Vaccine Trials Disease Research 52

The Pharma Data

DECEMBER 21, 2020

military scientists to determine if it might be resistant to vaccines. The deal also includes more than $30 billion to acquire and distribute coronavirus vaccines and $27 billion for testing and state health care programs. Higher flu vaccination rates are one reason why flu cases are way down in the United States, experts say.

Packaging 52

Packaging Vaccine Laboratories Virus 52

The Pharma Data

APRIL 14, 2021

The product’s early Marek’s disease onset of immunity from five days of age provides full protection of broilers, layers and breeders against the most virulent Marek’s disease virus strains. Its purpose is to provide poultry producers with cutting-edge technology in terms of Marek’s disease protection.

Vaccine 52

Vaccine Disease Virus Engineering 52

PPD

MAY 11, 2023

The global COVID-19 pandemic increased awareness of the importance of vaccine development — both for drug developers and the public. The speed at which COVID-19 vaccines were developed was remarkable, but like most newly developed vaccines, there was variation among who could receive the shots and when.

Vaccine 52

Vaccine Clinical Trials Long-Term Care Facilities Trials 52

Agency IQ

MARCH 7, 2024

Vaccines advisory panel endorses move to trivalent formulation for U.S. flu vaccines Yesterday, FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) weighed in on strains for seasonal influenza vaccines for the Northern hemisphere 2024-2025 season.

Vaccine 40

Vaccine FDA Virus Licensing 40

The Pharma Data

NOVEMBER 10, 2020

AHA: Young Adults With CVD Have Low Flu Vaccination Rates. 10, 2020 — Many young adults with cardiovascular disease (CVD) do not receive influenza vaccination, according to a study presented at the American Heart Association Scientific Sessions 2020, held virtually from Nov. © 2020 HealthDay.

Vaccine 52

Vaccine Disease Research 52

The Pharma Data

JANUARY 21, 2021

Percent of Kindergarteners Not Up to Date With MMR in 2019-2020. percent of kindergarteners were not up to date with measles, mumps, and rubella (MMR) vaccination and did not have an exemption in the 2019 to 2020 school year, according to research published in the Jan. The researchers found that vaccination coverage was 94.9,

Vaccine 52

Vaccine Disease Research 52

The Pharma Data

DECEMBER 31, 2020

Monthly News Roundup – December 2020. Moderna and Pfizer’s COVID-19 Vaccines Roll Out in Early Phase. Food and Drug Administration (FDA) issued Emergency Use Authorization for two COVID-19 vaccines: Pfizer-BioNTech’s BNT162b2 and Moderna’s mRNA-1273. The partial piece of the spike protein cannot cause COVID-19 disease.

FDA Approval 52

FDA Approval Vaccine FDA Treatment 52

The Pharma Data

DECEMBER 8, 2020

AstraZeneca (AZ) and the University of Oxford have presented new data from a “pooled analysis” of phase 3 trials evaluating COVID-19 vaccine AZD1222 at two different dose regimens, demonstrating an average efficacy of 70.4 The University of Oxford claims no vaccinated participants were hospitalized or suffered serious forms of the disease.

Vaccine 52

Vaccine Trials Hospitals Disease 52

The Pharma Data

NOVEMBER 3, 2020

Influenza Vaccination May Have Protective Effect on COVID-19. 3, 2020 — Influenza vaccination may have a protective effect for COVID-19 -positive patients, according to a brief report recently published in the Journal of the American Board of Family Medicine. Influenza vaccination status and comorbidities were examined.

Vaccine 52

Vaccine Hospitals Disease Research 52

The Pharma Data

JUNE 29, 2021

Sanofi will invest approximately €400 million annually in a first-of-its kind vaccines mRNA Center of Excellence. “During the COVID-19 pandemic, mRNA technologies demonstrated potential to deliver new vaccines faster than ever before. . ” said Thomas Triomphe, Executive Vice President, Global Head of Sanofi Pasteur.

Vaccine 52

Vaccine Disease International Treatment 52

The Pharma Data

DECEMBER 14, 2020

14, 2020 — The Pfizer-BioNTech COVID-19 vaccine has received the first emergency use authorization (EUA) for a COVID-19 vaccine in the United States. Centers for Disease Control and Prevention Director Robert R. The vaccine is administered in two doses three weeks apart. MONDAY, Dec. Redfield, M.D.,

Vaccine 52

Vaccine Nurses FDA Virus 52

The Pharma Data

OCTOBER 21, 2020

Fauci ‘Cautiously Optimistic’ for COVID-19 Vaccine by Year’s End. 21, 2020 — Anthony Fauci, M.D., the leading infectious disease expert in the United States, said on Wednesday he is “cautiously optimistic” that a COVID-19 vaccine will be ready by year’s end. © 2020 HealthDay.

Vaccine 52

Vaccine Disease Trials 52

The Pharma Data

JUNE 26, 2021

Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine. The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. JUNE 22 , 2021. We look forward to sharing initial results by year-end. ”. “

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

NOVEMBER 18, 2020

19, 2020 /PRNewswire/ — OBI Pharma, Inc. These results will be presented by the lead investigators of OBI Pharma’s novel anti-Globo H therapeutic cancer vaccine, OBI-833. In addition, OBI-833 can elicit a beneficial immune response in NSCLC patients and had rendered some TKI-treated patients a durable stable disease status.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

DECEMBER 17, 2020

Advisory Committee Votes to Recommend EUA for Moderna Vaccine. 17, 2020 — The Moderna COVID-19 vaccine received recommendation from a U.S. Food and Drug Administration advisory committee on Thursday, clearing the way for it to become the second COVID-19 vaccine to be granted emergency use authorization.

Vaccine 52

Vaccine Government Clinical Trials FDA 52

The Pharma Data

DECEMBER 8, 2020

8, 2020 — AstraZeneca’s COVID-19 vaccine is safe and effective, new data from late-stage trials shows. Overall, the vaccine protected against symptomatic disease in 70% of cases, according to a team led by researchers from Oxford University in England. TUESDAY, Dec. 8 in The Lancet.

Vaccine 52

Vaccine Trials Immune Response RNA 52

The Pharma Data

OCTOBER 23, 2020

CDC: Vaccination Coverage Generally High by Age 24 Months. 23, 2020 — Vaccination coverage with many recommended vaccines is high by age 24 months, according to research published in the Oct. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report. © 2020 HealthDay.

Vaccine 52

Vaccine Disease Research 52

The Pharma Data

JULY 8, 2021

People who receive mRNA COVID-19 vaccines are up to 91 percent less likely to develop the disease than those who are unvaccinated, according to a new nationwide study of eight sites, including Salt Lake City. Those who unfortunately got COVID-19 despite being vaccinated were still better off than those who didn’t.”

Vaccine 52

Vaccine Virus Nurses Hospitals 52

The Pharma Data

NOVEMBER 9, 2020

About One in Five Children Have Vaccine-Hesitant Parent. 9, 2020 — Parental vaccine hesitancy (VH) is reported for about 20 percent of children in the United States, according to a study published online Nov. © 2020 HealthDay. Posted: November 2020. Professional. MONDAY, Nov. 9 in Pediatrics. from the U.S.

Vaccine 52

Vaccine Disease Research 52

The Pharma Data

DECEMBER 22, 2020

22, 2020 — In very rare cases, some people have had severe allergic reactions after receiving the new COVID-19 vaccines, leading the American College of Allergy , Asthma, and Immunology (ACAAI) to issue updated guidance for Americans with allergies. © 2020 HealthDay. TUESDAY, Dec.

Vaccine 52

Vaccine Immune Response Treatment Disease 52

The Pharma Data

DECEMBER 11, 2020

11, 2020 — More than 15 million Americans have been infected by the COVID-19 virus, and many may be questioning whether they need to receive one of the two coronavirus vaccines now on the verge of approval from U.S. William Schaffner, a professor of infectious diseases at Vanderbilt University Medical Center in Nashville, Tenn.

Vaccine 52

Vaccine Immune Response Virus Trials 52

The Pharma Data

NOVEMBER 16, 2020

Moderna Vaccine Shows 94.5 16, 2020 — Moderna Inc. announced on Monday that early results show its COVID-19 vaccine is 94.5 The researchers behind the vaccine said the results were far better than they had hoped. National Institute of Allergy and Infectious Diseases. © 2020 HealthDay. Professional.

Vaccine 52

Vaccine Research Disease 52

The Pharma Data

DECEMBER 19, 2020

20, 2020 02:44 UTC. Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the U.S. 11 ACIP members voted in favor of the vaccine and 0 members voted against. We look forward to vaccinations of this important population starting this week.”. CAMBRIDGE, Mass.–(

Vaccine 52

Vaccine Long-Term Care Facilities FDA Licensing 52

The Pharma Data

NOVEMBER 29, 2020

AstraZeneca’s COVID-19 vaccine candidate is facing another potential delay as the company plans to undertake a new global clinical trial to confirm the vaccine’s 90 percent efficacy based on a one-and-a-half-dose regimen. The FDA’s vaccines advisory committee will meet on Dec. James Miessler.

Vaccine 52

Vaccine Trials FDA Clinical Trials 52

The Pharma Data

OCTOBER 20, 2020

No COVID-19 Vaccines Allowed in California Without State Approval. 20, 2020 — California is not going to allow the use of any COVID-19 vaccines until its own panel of experts approves them, Gov. Newsom’s statement may mean that Californians will not get a vaccine as distribution starts in other states, the AP said.

Vaccine 52

Vaccine Doctors Government Production 52

The Pharma Data

JULY 15, 2021

FreVAX is an innovative intramuscular needle free vaccine injection device for pigs around weaning until the end of nursery. FreVAX intramuscular needle free device has been available since December 2020 to swine producers globally. We develop solutions and provide services to protect animals from disease and pain.

Vaccine 52

Vaccine Compliance Disease 52

The Pharma Data

NOVEMBER 16, 2020

Moderna announced this week that its coronavirus vaccine, mRNA-1273, appears to not only be more effective than Pfizer’s candidate but has significantly less stringent temperature requirements as well, likely making distribution and storage of the vaccine an easier, less daunting task. percent efficacy rate. percent efficacy rate.

Vaccine 40

Vaccine Government Clinical Trials Disease 40

The Pharma Data

NOVEMBER 23, 2020

23, 2020 — The novel chimpanzee adenovirus-vectored vaccine, ChAdOx1 nCoV-19, is well tolerated, especially among older adults, according to a study published online Nov. During the study period, 13 serious adverse events occurred, none of which were considered to be related to the study vaccine. © 2020 HealthDay.

Vaccine 52

Vaccine Pharmaceutical Companies Pharmaceuticals Disease 52

The Pharma Data

DECEMBER 21, 2020

21, 2020 — A second COVID-19 vaccine is poised to be administered in the coming weeks after the U.S. Food and Drug Administration granted emergency use authorization (EUA) to the Moderna COVID-19 vaccine on Friday. The EUA allows for the vaccine to be administered to adults 18 years and older in two doses one month apart.

Vaccine 52

Vaccine FDA Hospitals Disease 52

The Pharma Data

JUNE 25, 2021

In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria. About CVnCoV. About CVnCoV.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

OCTOBER 27, 2020

Infectious Disease Least Severe in School-Aged Children. 27, 2020 — School-aged children seem to have the least severe disease for different infectious diseases, according to a study published online Oct. © 2020 HealthDay. . © 2020 HealthDay. Posted: October 2020. Professional. TUESDAY, Oct.

Disease 52

Disease Immune Response Vaccine Research 52

The Pharma Data

NOVEMBER 10, 2020

Canadian biopharmaceutical company Medicago has announced that its investigational COVID-19 vaccine generated “significant antibody and cellular immune responses” after two doses in all subjects in an early-stage clinical trial. microgram or 15-microgram doses of the vaccine candidate, either alone or with an adjuvant. microgram, 7.5-microgram

Immune Response 40

Immune Response Vaccine Clinical Trials Virus 40

The Pharma Data

JANUARY 7, 2021

Anaphylaxis Cases/Million Doses of Pfizer-BioNTech COVID-19 Vaccine Reported. 23, 2020, researchers determined there were 21 cases of anaphylaxis (11.1 per million doses administered) after receipt of the first dose of the Pfizer-BioNTech COVID-19 vaccine in the United States, according to research published in the Jan.

Vaccine 52

Vaccine Research Disease Drugs 52

National Drug & Alcohol Research Centre Blog

FEBRUARY 24, 2022

Olivia Price It has been one year since the COVID-19 vaccine rollout commenced in Australia, and while vaccination rates initially lagged behind other countries, over 95% of Australians aged 12 years and older are now fully vaccinated. We tend to consider the remaining unvaccinated people a homogenous ‘anti-vax’ group.

Vaccine 52

Vaccine Drugs Disease Pharmaceuticals 52

The Pharma Data

AUGUST 14, 2020

. AstraZeneca has announced the first shipment of Flumist Quadrivalent vaccine doses have been sent to the US for the upcoming influenza season. Flumist is currently the only nasal-spray flu vaccine and is indicated for use in individuals aged two through to 49. Source link.

Vaccine 52

Vaccine Production Disease 52

The Pharma Data

NOVEMBER 18, 2020

18, 2020 — Children should be included in clinical trials for a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine at the earliest stages, according to a letter from the president of the American Academy of Pediatrics (AAP), on behalf of more than 67,000 pediatricians and pediatric medical and surgical subspecialists.

Vaccine 52

Vaccine Trials Immune Response Virus 52